Last reviewed · How we verify

Cytran — Portfolio Competitive Intelligence Brief

Cytran pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
IM862 IM862 phase 3 Immunomodulatory peptide IL-2 pathway / T-cell activation Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Sun Yat-sen University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cytran:

Cite this brief

Drug Landscape (2026). Cytran — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cytran. Accessed 2026-05-15.

Related